LeMaitre Vascular, Inc. (NASDAQ:LMAT) Files An 8-K Entry into a Material Definitive Agreement

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.    Entry into a Material Definitive Agreement.

Story continues below

On November 26, 2019, LeMaitre Vascular, Inc. (the “Company”) entered into a new lease agreement (the “New Lease”) with NWP Retail 18 LLC for a property in Burlington, Massachusetts located at 32-34 Third Avenue. The building subject to the New Lease consists of approximately 26,447 square feet. The Company expects to occupy the building covered by the New Lease beginning on or around May 1, 2020. The New Lease will expire on December 31, 2030. The base rent for the property subject to the New Lease until December 31, 2021 will be $30,855 per month and will increase in each subsequent year of the New Lease.

The foregoing description of the New Lease is not complete and is qualified in its entirety by reference to the full text of such document attached as an exhibit hereto.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being filed with this Current Report on Form 8-K:

Exhibit        Document Description

10.1              Lease dated November 26, 2019 between NWP Retail 18 LLC and the Registrant.

 
 

LEMAITRE VASCULAR INC Exhibit
EX-10.1 2 ex_166228.htm EXHIBIT 10.1 ex_166228.htm   EXHIBIT 10.1               northwest park   OFFICE lease   by and between nwp retail 18 llc (AS LANDLORD)   and   LEMAITRE VASCULAR,…
To view the full exhibit click here

About LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

An ad to help with our costs